A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET).
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2015
At a glance
- Drugs Palbociclib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 23 Jul 2015 New trial record